More about

Ovarian Cancer

News
April 28, 2020
3 min read
Save

Intratumoral mRNA-2416 monotherapy appears safe for patients with solid tumors

Intratumoral mRNA-2416, a lipid nanoparticle therapeutic agent expressing the wild-type human OX40L, appeared safe among a cohort of patients with locally advanced, recurrent or metastatic solid tumors, according to results of a phase 1/2 first-in-human study presented at the virtual American Association for Cancer Research Annual Meeting.

News
April 11, 2020
1 min read
Save

Cancer researcher becomes The US Oncology Network’s chief scientific officer

Cancer researcher becomes The US Oncology Network’s chief scientific officer

The US Oncology Network named Robert L. Coleman, MD, FACOG, FACS, its new chief scientific officer.

News
April 02, 2020
2 min read
Save

Breastfeeding may reduce risk for ovarian cancer

Breastfeeding may reduce risk for ovarian cancer

Breastfeeding appeared to be associated with reduced risk for overall ovarian cancer and for the high-grade serous subtype, according to results of a pooled analysis published in JAMA Oncology.

News
March 31, 2020
4 min read
Save

Blood test detects dozens of cancer types, often before symptoms emerge

Blood test detects dozens of cancer types, often before symptoms emerge

A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology.

News
March 12, 2020
1 min read
Save

Phase 3 trial in relapsed ovarian cancer misses primary endpoint

Phase 3 trial in relapsed ovarian cancer misses primary endpoint

The combination of cediranib and olaparib failed to extend PFS compared with platinum-based chemotherapy for a subset of women with ovarian cancer, according to topline results of a randomized phase 3 trial.

News
February 27, 2020
1 min read
Save

FDA to conduct ‘real-time’ review of Zejula for advanced ovarian cancer

The FDA accepted a supplemental new drug application for niraparib as first-line maintenance treatment of women with platinum-responsive advanced ovarian cancer.

News
January 30, 2020
1 min read
Save

Incorporating belief in miracles into cancer care, other top stories in hematology/oncology

Insight into how clinicians can integrate belief in miracles into their discussions with terminally ill patients with advanced cancer was the top story in hematology/oncology last week.

News
January 13, 2020
2 min read
Save

FDA grants priority review to Lynparza as part of ovarian cancer maintenance regimen

The FDA granted priority review to olaparib in combination with bevacizumab as first-line maintenance treatment of women with advanced ovarian cancer, according to the agent’s manufacturer.

News
January 07, 2020
6 min read
Save

No significant link found between powder use, ovarian cancer

No significant link found between powder use, ovarian cancer

Researchers did not find a significantly higher risk for ovarian cancer in women who used powder in the genital area, according to an analysis of more than 250,000 women recently published in JAMA.

News
December 11, 2019
2 min read
Save

‘CA-125 is a valuable tool’ for women with ovarian cancer symptoms

‘CA-125 is a valuable tool’ for women with ovarian cancer symptoms

CA-125 is a “useful test” for ovarian cancer in primary care, especially in symptomatic women aged older than 50 years, according to a presenter at the recent National Cancer Research Institute Cancer Conference in Glasgow.

View more